Does PALBOCICLIB Cause Salivary hypersecretion? 33 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Salivary hypersecretion have been filed in association with PALBOCICLIB (Ibrance). This represents 0.0% of all adverse event reports for PALBOCICLIB.
33
Reports of Salivary hypersecretion with PALBOCICLIB
0.0%
of all PALBOCICLIB reports
4
Deaths
10
Hospitalizations
How Dangerous Is Salivary hypersecretion From PALBOCICLIB?
Of the 33 reports, 4 (12.1%) resulted in death, 10 (30.3%) required hospitalization.
Is Salivary hypersecretion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Salivary hypersecretion?
CLOZAPINE (1,349)
ARIPIPRAZOLE (497)
RISPERIDONE (485)
OLANZAPINE (449)
QUETIAPINE (299)
CARBIDOPA\LEVODOPA (248)
HALOPERIDOL (216)
DIAZEPAM (185)
CLONAZEPAM (179)
LORAZEPAM (165)
Which PALBOCICLIB Alternatives Have Lower Salivary hypersecretion Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID